FDA ApprovedUnited States
First FDA-Approved Treatment for Ataxia in Ataxia-Telangiectasia
Aqneursa (levacetylleucine) — oral suspension for ataxia in ataxia-telangiectasia
FDA labelled expansion on 18 September 2026 for Aqneursa (levacetylleucine) for oral suspension — for the treatment of ataxia in adult and pediatric patients…
This is for people living with ataxia-telangiectasia — and the caregivers who help them — who weigh at least 15 kg and may be candidates for labelled US…